In Vivo Topographic Associations Between Tau Pathology, Atrophy, and Symptom Domains in Patients With Progressive Supranuclear Palsy
BACKGROUND AND OBJECTIVES: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy characterized by subcortical atrophy and distinctive motor impairments. Although tau pathology is believed to drive neuronal loss, the spatial relationships among tau deposition, regional atrophy, and domain-specific symptoms remain incompletely understood. We aimed to determine how the topographic distribution of tau pathology and regional brain atrophy relate to distinct motor symptom domains in PSP and to clarify their contributions to clinical manifestations. METHODS: A single-center, cross-sectional study was conducted. Patients with PSP were recruited after diagnosis at neurology departments and were referred to our institution. All PSP cases underwent neurologic assessments, including PSP Rating Scale. Tau PET imaging with florzolotau (18F) and T1-weighted magnetic resonance imaging were obtained from patients and healthy controls to assess associations between domain scores, tau accumulation, and regional brain volumes. Path analysis was used to examine whether cross-sectional associations were consistent with hypothesized relationships among tau deposits, regional atrophy, and symptom domains. RESULTS: < 0.05. Path analysis indicated that tau in subcortical structures was associated with local neuronal loss and with impairments in the ocular motor and gait and midline domains. DISCUSSION: High-contrast tau imaging clarifies the neuropathologic basis of key symptoms and underscores distinct tau-induced neurotoxic effects in subcortical vs neocortical regions. Specifically, tau deposition in the neocortex may contribute to limb motor impairments through local effects and potentially through more distributed neurodegenerative processes. These findings support anatomically distinct tau-neurodegeneration pathways underlying key PSP symptom domains.
Authors
- Makoto Higuchi (ORCID: https://orcid.org/0000-0002-3934-5810)
- Keisuke Takahata (ORCID: https://orcid.org/0000-0002-0884-4924)
- Masaki Oya (ORCID: https://orcid.org/0009-0003-7709-9520)
- Shin Kurose (ORCID: https://orcid.org/0000-0001-8355-4946)
- Naomi Kokubo (ORCID: https://orcid.org/0000-0002-6904-9107)
- Hironobu Endo (ORCID: https://orcid.org/0000-0003-3398-597X)
- Masanori Ichihashi (ORCID: https://orcid.org/0009-0001-0431-4125)
- Ryoji Goto (ORCID: https://orcid.org/0000-0002-1693-9915)
- Sho Moriguchi (ORCID: https://orcid.org/0000-0001-7536-9708)
- Kiwamu Matsuoka (ORCID: https://orcid.org/0000-0003-3263-0958)
- Chie Seki (ORCID: https://orcid.org/0000-0002-3222-7125)
- Yuki Momota
- Kosei Hirata (ORCID: https://orcid.org/0009-0007-9027-9277)
- Hitoshi Shimada (ORCID: https://orcid.org/0000-0002-7139-7178)
- Kenji Tagai (ORCID: https://orcid.org/0000-0002-4551-1491)
- Hitoshi Shinotoh (ORCID: https://orcid.org/0000-0003-1726-8268)
- Hideki Matsumoto (ORCID: https://orcid.org/0000-0002-8057-9598)
- Takahiko Tokuda (ORCID: https://orcid.org/0000-0002-7411-4911)
- Ming-Rong Zhang
Institutions
- Tokyo Dental College (JP)
- National Institutes for Quantum Science and Technology (JP)
- Osaka Metropolitan University (JP)
- Brain Research Institute, Niigata University (JP)
- Institute for Quantum Medical Science (JP)
- Niigata University (JP)
Publication Details
- Journal
- Neurology
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1212/wnl.0000000000218693
- Citations
- 3
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.34
Funders
- Biogen
- Japan Agency for Medical Research and Development
- Keio University
- Ministry of Education, Culture, Sports, Science and Technology
- University of Tsukuba
- Tokyo Medical and Dental University
- Chiba University
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency